Publication
ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerMalignant Breast Neoplasmcivic_curation1.00
- geneABCB1civic_curation1.00
- geneFCGR2Acivic_curation1.00
- geneFCGR3Acivic_curation1.00
- variantABCB1 I1145Icivic_curation1.00
- variantABCB1 S893A/Tcivic_curation1.00
- variantFCGR2A H167Rcivic_curation1.00
- variantFCGR3A F212Vcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22906996
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABCB1 I1145I1 | ||||||||
| (prognostic) | Malignant Breast Neoplasm | Prognostic | B | Supports Better Outcome | 3 | accepted | EID1076A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 C3435T carriers had a longer progression-free survival (p = 0.039) along… (full text at CIViC) PMID 22906996 · Kim et al., 2012 · Open in CIViC | civic |
| ABCB1 S893A/T1 | ||||||||
| (prognostic) | Malignant Breast Neoplasm | Prognostic | B | Supports Better Outcome | 3 | accepted | EID1075A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 G2677T carriers had a longer progression-free survival (p = 0.037) along… (full text at CIViC) PMID 22906996 · Kim et al., 2012 · Open in CIViC | civic |
| FCGR2A H167R1 | ||||||||
| (prognostic) | Malignant Breast Neoplasm | Prognostic | B | Does Not Support N/A | 3 | accepted | EID1084A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR2A H131R carriers did not have a significantly different response rate, pr… (full text at CIViC) PMID 22906996 · Kim et al., 2012 · Open in CIViC | civic |
| FCGR3A F212V1 | ||||||||
| (prognostic) | Malignant Breast Neoplasm | Prognostic | B | Does Not Support N/A | 3 | accepted | EID1085A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR3A V158F carriers did not have a significantly different response rate, pr… (full text at CIViC) PMID 22906996 · Kim et al., 2012 · Open in CIViC | civic |